Glucophage Xr

Glucophage XR is a prescription oral medication containing metformin hydrochloride, a biguanide antidiabetic agent, available in extended‑release tablets. It is marketed in the European Union and is used to improve glycemic control in adults with type 2 diabetes mellitus. The formulation provides a gradual release of the active ingredient, allowing once‑daily dosing and potentially reducing gastrointestinal discomfort compared with immediate‑release versions. It should be taken with food.

Glucophage XR is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan that includes diet and exercise.

- Improves fasting and postprandial blood glucose levels. - Used as monotherapy when metformin alone is sufficient. - Can be combined with other oral antidiabetic agents or insulin. - May be prescribed when a patient requires a simplified once‑daily regimen. - Helps reduce HbA1c when used consistently over several weeks. - May be considered in patients with mild to moderate renal function, following dosing guidelines.

The safety profile of Glucophage XR reflects the known effects of metformin, with most patients experiencing mild, transient symptoms while serious reactions are uncommon.

Common: - Nausea or upset stomach. - Diarrhea or loose stools. - Abdominal discomfort or cramping. - Metallic taste in the mouth. - Loss of appetite. - Weight loss.

Serious: - Lactic acidosis, a rare metabolic emergency. - Severe skin reactions such as Stevens‑Johnson syndrome. - Hepatotoxicity (liver enzyme elevation).

When prescribing Glucophage XR, clinicians should evaluate patient history and laboratory values to minimize risks and ensure appropriate use.

- Assess renal function before initiation and periodically thereafter. - Avoid use in patients with known hypersensitivity to metformin. - Use with caution in hepatic impairment or alcohol misuse. - Monitor for signs of vitamin B12 deficiency during long‑term therapy. - Adjust dose in elderly patients due to altered pharmacokinetics. - Discontinue before any iodinated contrast imaging that may affect kidney function.

Glucophage XR may interact with other medicines, influencing blood glucose control or increasing the risk of adverse effects.

Avoid: - Iodinated radiographic contrast agents (may cause acute kidney injury). - Cimetidine (can increase metformin plasma concentrations).

Use with caution: - Diuretics, ACE inhibitors, or ARBs (risk of renal function decline). - Beta‑blockers (may mask hypoglycemia symptoms). - Corticosteroids (can raise blood glucose). - Alcohol (enhances risk of lactic acidosis).